Atlas Trials

Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

Clinical trial NCT03594396 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03594396
Sponsor
Seoul National University Hospital
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Breast Neoplasms
Start date
2018-06-29
Primary completion
2025-12-31
Enrollment
54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.